Publications by authors named "Sari Hernesniemi"
Article Synopsis
- 1L immunotherapy has shown better overall survival rates in metastatic melanoma compared to 1L targeted therapy, especially for eligible patients.
- A study in Finland (2014-2021) compared outcomes of patients treated with 1L immunotherapy vs. 1L targeted therapy, highlighting significant differences in survival rates and baseline characteristics.
- Patients receiving 1L immunotherapy had fewer severe baseline conditions and higher 2-year survival rates (60.3-63.5%) compared to those on 1L targeted therapy (33.8%).
Clever-1/Stabilin-1 is a scavenger receptor present on lymphatic and sinusoidal endothelium as well as on a subset of type II macrophages. It is also induced on vasculature at sites of inflammation. However, its in vivo function has remained practically unknown and this work addresses those unknown aspects.
View Article and Find Full Text PDF